Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Breast Neoplasms 1

Interventions

Docetaxel 3Carboplatin 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2Paclitaxel 2vandetanib 1temoporfin 1tanespimycin 1Vinorelbine 1Temozolomide 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Oxaliplatin 1Gemcitabine 1Everolimus 1Erlotinib Hydrochloride 1Crizotinib 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Large Cell × figitumumab × Thoracic × Clear all
NCT00596830 2014-01-13

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Pfizer

Phase 3 Terminated
681 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell

NCT00673049 2013-07-24

NSCLC

Pfizer

Phase 3 Terminated
583 enrolled 11 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡